Visualization of Anti-angiogenic Effects With Perfusion Computed Tomography (CTP) (AVA-CTP)

December 15, 2016 updated by: Patrick Veit-Haibach

Visualization of Anti-angiogenic Effects With Perfusion Computed Tomography (CTP) in mCRC Patients Treated With First-line Bevacizumab

The primary objective of this study is to investigate the anti-angiogenic effect of bevacizumab measured by CTP as a predictive marker for efficacy measured by progression-free survival (PFS) in mCRC patients under first-line bevacizumab-containing, fluoropyrimidine-based chemotherapy

Study Overview

Status

Terminated

Detailed Description

So far, CTP has provided non-invasive imaging of tumor biological response to anti-angiogenic and vascular targeting agents in a number of clinical trials with increasing clinical application. CTP can be examined with a variety of commercially available CE-certified CT scanners and imaging post-processing is possible with commercially available CE-certified software from different vendors, too. In several studies, anti-angiogenic effects have been detected with CTP but further evidence for its clinical validation has to be proven in clinical trials.

Changes in tumor vasculature measured by CTP will be correlated to the clinical efficacy parameters progression-free survival, overall survival and response rate, thus identifying a group of patients who profit most from the anti-angiogenic treatment.

Study Type

Interventional

Enrollment (Anticipated)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • GR
      • Chur, GR, Switzerland, 7000
        • Kantonsspital Graubünden
    • LU
      • Luzern, LU, Switzerland, 6000
        • Luzerner Kantonsspital
    • SG
      • St. Gallen, SG, Switzerland, 9007
        • Kantonsspital St. Gallen
    • ZH
      • Winterthur, ZH, Switzerland, 8401
        • Kantonsspital Winterthur
      • Zürich, ZH, Switzerland, 8091
        • Universitätsspital Zürich

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age ≥ 18 years, male or female
  • Signed written informed consent
  • Patients with histologically confirmed diagnosis of colorectal cancer with hepatic metastases who are candidates for systemic treatment.
  • Confirmation of metastatic liver disease within one month prior to inclusion in one of the following radiological procedures:

    • Contrast-enhanced spiral computed tomography showing at least one liver nodule ≥ 20 mm in longest diameter according to RECIST 1.1 criteria
    • MR imaging of the liver with liver lesions suspicious for metastases
    • PET computed tomography (PET/CT) with liver lesions suspicious for metastases
  • Patient is eligible and designated for treatment with standard-of-care first-line bevacizumab-containing, fluoropyrimidine-based chemotherapy.
  • ECOG performance status ≤ 2 (see appendix)

Exclusion Criteria:

  • Inability or unwillingness to comply with the participation requirements
  • History of untreated hyperthyreosis
  • History of intolerance of or allergy to iodine contrast media according to CTCAE V4.03
  • Calculated creatinine clearance < 45 ml/min
  • For fertile women: positive urine pregnancy test or lactation.
  • Known or suspected non-compliance, drug or alcohol abuse
  • Life expectancy of less than 3 months
  • Participation in another interventional trial with an investigational medicinal product (IMP) and within 30 days prior to screening

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Perfusion-computed tomography (CTP)
Patients undergo a total of four perfusion-computed tomographies from baseline to progression of disease.
Contrast-enhanced computed tomography of liver metastases
Other Names:
  • CT scanner

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
CTP as predictive marker for efficacy measured by progression-free survival
Time Frame: one year
Predictive power of decrease in tumor vasculature on the clinical outcome in bevacizumab-based chemotherapy measured by progression-free survival (PFS). Decrease in tumor vasculature is measured by blood flow in CTP 3 compared to CTP 1 (baseline)
one year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
CTP as predictive marker for efficacy measured by progression-free survival
Time Frame: one year
Predictive power of decrease in tumor vasculature on the clinical outcome in bevacizumab-based chemotherapy measured by progression-free survival (PFS). Decrease in tumor vasculature is measured by blood flow, blood volume, mean transit time and permeability surface-area product in CTP
one year
CTP as predictive marker for efficacy measured by overall survival
Time Frame: four years
Predictive power of decrease in tumor vasculature measured by CTP on the clinical outcome in bevacizumab-based chemotherapy measured by overall survival (OS)
four years
Tumor vasculature at progression
Time Frame: one year
Tumor vasculature measured by blood flow, blood volume, mean transit time and permeability surface-area product in CTP at the time of confirmed progression
one year
Subgroup analyses according to the RAS mutation status, BRAF mutation status and VEGF-A level
Time Frame: one year
Predictive power of RAS-mutation status, BRAF-mutation status and VEGF-A level on the clinical outcome in bevacizumab-based chemotherapy measured by progression-free survival (PFS)
one year
Local and distant recurrences
Time Frame: one year
Rates of local and distant recurrences according to RECIST 1.1 criteria
one year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Patrick Veit-Haibach, MD, University Hospital Zurich, Diagnostic and Interventional Radiology

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2015

Primary Completion (Actual)

December 1, 2016

Study Completion (Anticipated)

April 1, 2017

Study Registration Dates

First Submitted

April 29, 2015

First Submitted That Met QC Criteria

July 27, 2015

First Posted (Estimate)

July 30, 2015

Study Record Updates

Last Update Posted (Estimate)

December 16, 2016

Last Update Submitted That Met QC Criteria

December 15, 2016

Last Verified

December 1, 2016

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Metastatic Colorectal Cancer

Clinical Trials on Computed tomography X-ray system

3
Subscribe